Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y
Department of Ophthalmology, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
Br J Ophthalmol. 2008 Jan;92(1):70-3. doi: 10.1136/bjo.2007.122283. Epub 2007 Jun 13.
The aim of the study was to assess the short-term efficacy of intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV).
Intravitreal bevacizumab (1 mg) was injected into 11 eyes of 11 patients with PCV in this retrospective, interventional case series. The main outcome measure was the change in the polypoidal vessels on indocyanine green angiography (IA) 3 months after injection. The foveal height determined by optical coherence tomography and the best-corrected visual acuity (BCVA) also were evaluated before and after treatment.
At baseline, subretinal fluid was observed in five eyes and a pigment epithelial detachment in eight eyes. The foveal height 1 month after injection decreased significantly (p = 0.023), but at 3 months, no significant decrease was observed, although an additional injection was administrated in five of 11 eyes. The IA at 3 months showed resolution of polyps in one eye but residual or enlarged lesions in the other ten eyes. The BCVA did not improve significantly, although the subjects had relatively good BCVA at baseline (mean 0.45).
Intravitreal injection of bevacizumab may reduce the fluid from PCV but seems to be ineffective for diminishing its choroidal vascular changes.
本研究旨在评估玻璃体内注射贝伐单抗治疗息肉样脉络膜血管病变（PCV）的短期疗效。
在这个回顾性、介入性病例系列研究中，对11例PCV患者的11只眼玻璃体内注射贝伐单抗（1毫克）。主要观察指标是注射后3个月吲哚菁绿血管造影（IA）上息肉样血管的变化。还在治疗前后评估了光学相干断层扫描测定的黄斑高度和最佳矫正视力（BCVA）。
基线时，5只眼观察到视网膜下液，8只眼观察到色素上皮脱离。注射后1个月黄斑高度显著降低（p = 0.023），但在3个月时，尽管11只眼中有5只眼进行了额外注射，未观察到显著降低。3个月时的IA显示1只眼息肉消退，但其他10只眼有残留或增大的病变。尽管受试者在基线时BCVA相对较好（平均0.45），但BCVA没有显著改善。
玻璃体内注射贝伐单抗可能减少PCV的积液，但似乎对减轻其脉络膜血管变化无效。
